aNew York City Department of Health and Mental Hygiene, Bureau of Alcohol and Drug Use Prevention, Care, and Treatment Queens, Queens, New York, USA.
New York City Department of Health and Mental Hygiene, Bureau of Alcohol and Drug Use Prevention, Care, and Treatment Queens, Queens, New York, USA.
Subst Abus. 2019;40(4):459-465. doi: 10.1080/08897077.2019.1640833. Epub 2019 Sep 24.
There is consensus in the scientific literature that the opioid agonist medications methadone and buprenorphine are the most effective treatments for opioid use disorder. Despite increasing opioid overdose deaths in the United States, these medications remain substantially underutilized. For no other medical conditions for which an effective treatment exists is that treatment used so infrequently. In this commentary, we discuss the potential role of stigma in the underutilization of these opioid agonist medications for addiction treatment. We outline stigma toward medications for addiction treatment and suggest that structural and policy barriers to methadone and buprenorphine may contribute to this stigma. We offer pragmatic public health solutions to reduce stigma and expand access to these effective treatments.
科学文献中有共识认为,阿片类激动剂药物美沙酮和丁丙诺啡是治疗阿片类药物使用障碍最有效的药物。尽管美国阿片类药物过量死亡人数不断增加,但这些药物的使用仍然大大不足。对于任何其他有有效治疗方法的医疗条件,这种治疗方法都不会如此频繁地使用。在这篇评论中,我们讨论了污名化在这些阿片类激动剂药物治疗成瘾方面使用不足的潜在作用。我们概述了针对成瘾治疗药物的污名,并认为美沙酮和丁丙诺啡的结构和政策障碍可能导致了这种污名。我们提供了切实可行的公共卫生解决方案,以减少污名化,并扩大这些有效治疗方法的使用。